Advances in Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing

Watch this interactive, on-demand Webcast led by George D. Demetri, MD, and featuring an expert panel discussing best practices in testing for NTRK fusions in solid tumors, current evidence supporting the use of approved TRK inhibitors, and emerging topics, including TRK inhibitor resistance and second-generation agents.

George D. Demetri, MD
Program Director Alexander Drilon, MD Pashtoon M. Kasi, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 21, 2020 Expired: No longer available for credit

Introduction (2 mins)

Rationale for Targeting TRK Fusions in Solid Tumors and Implementing NTRK Testing in the Clinic (20 mins)

Clinical Data and Current Indications for TRK Inhibitors (19 mins)

TRK Inhibitor Resistance and Safety (19 mins)

Listen to George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer audience questions from a series of live CCO Webinars focused on when and how to test for NTRK fusions in solid tumors and best practices in using TRK inhibitors.

George D. Demetri, MD
Program Director Alexander Drilon, MD Pashtoon M. Kasi, MD, MS Released: August 14, 2020

Download this slideset for expert perspectives on current best practices in testing for NTRK fusions in solid tumors.

George D. Demetri, MD Released: July 10, 2020

Download this slideset for expert perspectives on current best practices in the use of approved TRK inhibitors for patients with solid tumors.

Pashtoon M. Kasi, MD, MS Released: July 10, 2020

Download this slideset for expert perspectives on emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents, as well key adverse events with TRK inhibitors and management strategies.

Alexander Drilon, MD Released: July 10, 2020

Read my thoughts on how I approach TRK inhibitor therapy, including testing for NTRK fusions and monitoring for adverse events.

Alexander Drilon, MD Released: July 10, 2020